Skip to main content
×
Home
    • Aa
    • Aa

Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frameworks

  • Barbara S. van der Meij (a1), Coline P. Schoonbeek (a1), Egbert F. Smit (a2), Maurizio Muscaritoli (a3), Paul A. M. van Leeuwen (a4) and Jacqueline A. E. Langius (a1)...
Abstract

Despite the development of consensus-based frameworks to define cancer cachexia, the validity and usefulness of these frameworks are relatively unknown. The aim of the present study was to study the presence of pre-cachexia and cachexia in patients with stage III non-small-cell lung carcinoma (NSCLC) by using a cancer-specific framework and a general framework for cachexia, and to explore the prognostic value of pre-cachexia and cachexia. In forty patients at diagnosis of stage III NSCLC, weight loss, fat-free mass, handgrip strength, anorexia and serum biochemistry, assessed before the first chemotherapy, were used to define ‘cancer cachexia’ or ‘cachexia’. The cancer-specific framework also classified for pre-cachexia and refractory cachexia. Additionally, quality of life was assessed by the European Organisation for Research and Treatment of Cancer – Quality of Life Questionnaire C30. Groups were compared using independent t tests, ANOVA, Kaplan–Meier and Cox survival analyses. Based on the cancer-specific framework, pre-cachexia was present in nine patients (23 %) and cancer cachexia was present in seven patients (18 %). Cancer cachexia was associated with a reduced quality of life (P= 0·03) and shorter survival (hazard ratio (HR) = 2·9; P= 0·04). When using the general framework, cachexia was present in eleven patients (28 %), and was associated with a reduced quality of life (P= 0·08) and shorter survival (HR = 4·4; P= 0·001). In conclusion, pre-cachexia and cachexia are prevalent in this small population of patients at diagnosis of stage III NSCLC. For both frameworks, cachexia appears to be associated with a reduced quality of life and shorter survival. Further studies are warranted to more extensively explore the validity and prognostic value of these new frameworks in cancer patients.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frameworks
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frameworks
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: an exploratory study comparing two consensus-based frameworks
      Available formats
      ×
Copyright
Corresponding author
*Corresponding author: B. S. van der Meij, fax +31 20 444 4143, email b.vandermeij@vumc.nl
References
Hide All
1Muscaritoli M, Anker SD, Argiles J, et al. (2010) Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr 29, 154159.
2Van Cutsem E & Arends J (2005) The causes and consequences of cancer-associated malnutrition. Eur J Oncol Nurs 9, S51S63.
3Davis MP & Dickerson D (2000) Cachexia and anorexia: cancer's covert killer. Support Care Cancer 8, 180187.
4Fearon K, Strasser F, Anker SD, et al. (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12, 489495.
5Evans WJ, Morley JE, Argiles J, et al. (2008) Cachexia: a new definition. Clin Nutr 27, 793799.
6Bozzetti F & Mariani L (2009) Defining and classifying cancer cachexia: a proposal by the SCRINIO Working Group. JPEN J Parenter Enteral Nutr 33, 361367.
7Fox KM, Brooks JM, Gandra SR, et al. (2009) Estimation of cachexia among cancer patients based on four definitions. J Oncol 2009, 693458.
8Argiles JM, Lopez-Soriano FJ, Toledo M, et al. (2011) The cachexia score (CASCO): a new tool for staging cachectic cancer patients. J Cachex Sarcopenia Muscle 2, 8793.
9Ross PJ, Ashley S, Norton A, et al. (2004) Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer 90, 19051911.
10Dewys WD, Begg C, Lavin PT, et al. (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69, 491497.
11Laviano A & Meguid MM (1996) Nutritional issues in cancer management. Nutrition 12, 358371.
12Simons JP, Schols AM, Buurman WA, et al. (1999) Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin Sci (Lond) 97, 215223.
13Staal-van den Brekel AJ, Dentener MA, Schols AM, et al. (1995) Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 13, 26002605.
14Ovesen L, Hannibal J & Mortensen EL (1993) The interrelationship of weight loss, dietary intake, and quality of life in ambulatory patients with cancer of the lung, breast, and ovary. Nutr Cancer 19, 159167.
15Mohan A, Singh P, Kumar S, et al. (2008) Effect of change in symptoms, respiratory status, nutritional profile and quality of life on response to treatment for advanced non-small cell lung cancer. Asian Pac J Cancer Prev 9, 557562.
16Martin F, Santolaria F, Batista N, et al. (1999) Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 11, 8086.
17Meij van der BS, Langius JAE, Smit EF, et al. (2010) Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment. J Nutr 140, 17741780.
18Lukaski HC, Bolonchuk WW, Hall CB, et al. (1986) Validation of tetrapolar bioelectrical impedance method to assess human body composition. J Appl Physiol 60, 13271332.
19Houtkooper LB, Lohman TG, Going SB, et al. (1996) Why bioelectrical impedance analysis should be used for estimating adiposity. Am J Clin Nutr 64, 436S448S.
20Kyle UG, Genton L, Karsegard L, et al. (2001) Single prediction equation for bioelectrical impedance analysis in adults aged 20–94 years. Nutrition 17, 248253.
21Gupta D, Lammersfeld CA, Vashi PG, et al. (2009) Bioelectrical impedance phase angle in clinical practice: implications for prognosis in stage IIIB and IV non-small cell lung cancer. BMC Cancer 9, 37.
22Weir JB (1949) New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 109, 19.
23Mansell PI & Macdonald IA (1990) Reappraisal of the Weir equation for calculation of metabolic rate. Am J Physiol 258, R1347R1354.
24Moses AW, Slater C, Preston T, et al. (2004) Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids. Br J Cancer 90, 9961002.
25Wilson MM, Thomas DR, Rubenstein LZ, et al. (2005) Appetite assessment: simple appetite questionnaire predicts weight loss in community-dwelling adults and nursing home residents. Am J Clin Nutr 82, 10741081.
26Burtis CA, Ashwood ER & Tietz NW (1994) Tietz Textbook of Clinical Chemistry, 2nd ed.Philadelphia: W.B. Saundersen Company.
27Purich DL & Allison RD (2000) Handbook of Biochemical Kinetics. San Diego: Academic Press.
28Dati F, Johnson AM & Whicher JT (2001) The existing interim consensus reference ranges and the future approach. Clin Chem Lab Med 39, 11341136.
29Bohannon RW, Peolsson A, Massy-Westropp N, et al. (2006) Reference values for adult grip strength measured with a Jamar dynamometer: a descriptive meta-analysis. Physiotherapy 92, 1115.
30Yates JW, Chalmer B & McKegney FP (1980) Evaluation of patients with advanced cancer using the Karnofsky performance status. Nat Rev Cancer 45, 22202224.
31Karnofsky DA & Burchenal JH (1949) Evaluation of chemotherapeutic agents. In The Clinical Evaluation of Chemotherapeutic Agents in Cancer, p. 196 [MacLeod CM, editor]. Columbia: Columbia University Press.
32Slootmaker SM, Chinapaw MJ, Schuit AJ, et al. (2005) Promoting physical activity using an activity monitor and a tailored web-based advice: design of a randomized controlled trial [ISRCTN93896459]. BMC Public Health 5, 134.
33Slootmaker SM, Chinapaw MJ, Schuit AJ, et al. (2009) Concurrent validity of the PAM accelerometer relative to the MTI Actigraph using oxygen consumption as a reference. Scand J Med Sci Sports 19, 3643.
34Schutz Y, Kyle UU & Pichard C (2002) Fat-free mass index and fat mass index percentiles in Caucasians aged 18–98 y. Int J Obes Relat Metab Disord 26, 953960.
35Fearon KC, Voss AC & Hustead DS (2006) Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83, 13451350.
36Andreyev HJ, Norman AR, Oates J, et al. (1998) Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer 34, 503509.
37McMillan DC, Crozier JE, Canna K, et al. (2007) Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 22, 881886.
38Jiang X, Hiki N, Nunobe S, et al. (2012) Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer. Br J Cancer 107, 275279.
39Murphy RA, Mourtzakis M, Chu QS, et al. (2011) Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Nat Rev Cancer 117, 37743780.
40Aronson WJ, Kobayashi N, Barnard RJ, et al. (2011) Phase II prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy. Cancer Prev Res (Phila) 4, 20622071.
41Staal-van den Brekel AJ, Schols AMWJ, ten Velde GPM, et al. (1994) Analysis of the energy balance in lung cancer patients. Cancer Res 54, 64306433.
42Op den Kamp CM, Langen RC, Minnaard R, et al. (2012) Pre-cachexia in patients with stages I–III non-small cell lung cancer: Systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system. Lung Cancer 76, 112117.
43Fredrix EW, Soeters PB, Wouters EF, et al. (1991) Effect of different tumor types on resting energy expenditure. Cancer Res 15, 61386141.
44Staal-van den Brekel AJ, Schols AM, Dentener MA, et al. (1997) The effects of treatment with chemotherapy on energy metabolism and inflammatory mediators in small-cell lung carcinoma. Br J Cancer 76, 16301635.
45Giannousi Z, Gioulbasanis I, Pallis AG, et al. (2012) Nutritional status, acute phase response and depression in metastatic lung cancer patients: correlations and association prognosis. Support Care Cancer 20, 18231829.
46Gioulbasanis I, Georgoulias P, Vlachostergios PJ, et al. (2011) Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: interrelations and associations with prognosis. Lung Cancer 74, 516520.
47Coups EJ, Park BJ, Feinstein MB, et al. (2009) Physical activity among lung cancer survivors: changes across the cancer trajectory and associations with quality of life. Cancer Epidemiol Biomarkers Prev 18, 664672.
48Gibney E, Elia M, Jebb SA, et al. (1997) Total energy expenditure in patients with small-cell lung cancer: results of a validated study using the bicarbonate-urea method. Metabolism 46, 14121417.
49Tisdale MJ (2008) Catabolic mediators of cancer cachexia. Curr Opin Support Palliat Care 2, 256261.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

British Journal of Nutrition
  • ISSN: 0007-1145
  • EISSN: 1475-2662
  • URL: /core/journals/british-journal-of-nutrition
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords:

Type Description Title
PDF
Supplementary Materials

van der Meij supplementary material
van der Meij supplementary material

 PDF (28 KB)
28 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 6
Total number of PDF views: 171 *
Loading metrics...

Abstract views

Total abstract views: 233 *
Loading metrics...

* Views captured on Cambridge Core between September 2016 - 21st October 2017. This data will be updated every 24 hours.